Form 4: ARS Pharmaceuticals Chief Medical Officer Sells Shares Under 10b5-1 Plan

ARS Pharmaceuticals' Chief Medical Officer, Sarina Tanimoto, sold 100,000 shares of common stock through trusts under a pre-arranged 10b5-1 trading plan.

Summary

• Sarina Tanimoto, the Chief Medical Officer of ARS Pharmaceuticals, sold a total of 100,000 shares of common stock.
• The sales were executed through multiple trusts, including the Richard Lowenthal Charitable Remainder UniTrust and the Lowenthal-Tanimoto Family Trust.
• The transactions were conducted under a Rule 10b5-1 trading plan established on March 31, 2023.
• 50,000 shares were sold at a weighted average price of $13.1653, with prices ranging from $12.94 to $13.535.
• Another 50,000 shares were sold at a weighted average price of $13.1631, with prices also ranging from $12.94 to $13.535.
• The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Sentiment

Score: 5

Explanation: The document reports a routine stock sale by an executive under a pre-arranged plan. There is no indication of positive or negative sentiment, it is a neutral event.

Risks

• Sales by company insiders can sometimes be perceived negatively by the market, potentially impacting the stock price.

Management Comments

• The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Industry Context

Sales by insiders are a common occurrence and are often pre-planned to avoid accusations of trading on non-public information. The use of a 10b5-1 plan is a standard practice for executives to manage their stock holdings.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies, including those in the pharmaceutical sector such as Amgen, Gilead Sciences, and Regeneron.
• These plans allow insiders to sell shares without being accused of trading on material non-public information, aligning with SEC regulations and industry best practices.
• The reported sale prices are within the typical range for stock transactions, and the disclosure is consistent with standard SEC reporting requirements.

Stakeholder Impact

• The stock sale may have a minor impact on shareholder sentiment, but the pre-planned nature of the transaction should mitigate any significant concerns.

Key Dates

Keywords

ARS Pharmaceuticals, Sarina Tanimoto, insider trading, stock sale, Rule 10b5-1, Chief Medical Officer, common stock